Bacteriophage-Based Therapeutics for Selective Elimination of Healthcare-Associated Pathogens

Abstract

Bacteriophage-based therapeutics have emerged as a promising modality for the targeted elimination of healthcare-associated pathogens, especially in the era of escalating antimicrobial resistance. By leveraging the specificity of phages to lyse pathogenic bacteria without disturbing commensal flora, this approach offers a precision medicine strategy with significant clinical and epidemiological implications. This review evaluates the scientific rationale, mechanisms, clinical evidence, and practical considerations for integrating bacteriophage therapy into the management of healthcare-associated infections (HAIs), drawing upon recent research, evolving guidelines, and expert consensus.

Introduction

Healthcare-associated infections remain a significant challenge in modern medicine, contributing to increased morbidity, mortality, and healthcare costs globally. The rise of multidrug-resistant (MDR) organisms has limited treatment options and highlighted the urgent need for alternative antimicrobial strategies. Bacteriophage (phage) therapy, once overshadowed by antibiotics, is regaining clinical interest due to its ability to selectively target pathogenic bacteria. This article explores the clinical application of bacteriophages for the selective elimination of HAIs, emphasizing recent advances, underlying mechanisms, and evolving clinical guidelines.

Epidemiology / Disease Burden

Globally, HAIs affect hundreds of millions of patients annually, with the World Health Organization estimating that 7-10% of hospitalized patients acquire at least one HAI. The burden is particularly pronounced in intensive care units and among immunocompromised individuals. Key pathogens include methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococci (VRE), carbapenem-resistant Enterobacteriaceae (CRE), Acinetobacter baumannii, and Pseudomonas aeruginosa. The growing prevalence of MDR strains has rendered conventional antibiotics increasingly ineffective, leading to prolonged hospital stays, higher medical costs, and elevated mortality rates.

Pathophysiology

Bacteriophages are viruses that infect and lyse specific bacterial hosts. Their life cycle involves adsorption to the bacterial surface, injection of genetic material, replication within the host, and eventual lysis of the bacterium, releasing progeny phages. The host-range specificity of phages is determined by bacterial surface receptors, conferring selectivity that can be harnessed for targeted pathogen eradication. Unlike broad-spectrum antibiotics, phages typically do not disrupt the commensal microbiome, potentially minimizing dysbiosis and secondary infections such as Clostridioides difficile colitis.

Risk Factors

Patients at highest risk for HAIs include those with prolonged hospitalizations, indwelling devices (e.g., catheters, ventilators), immunosuppression, exposure to invasive procedures, and prior antibiotic use. The persistence of MDR organisms in the hospital environment, coupled with lapses in infection control, amplifies transmission risk. Patient populations in oncology, solid organ transplantation, and critical care settings are particularly vulnerable to recalcitrant infections unresponsive to standard therapies.

Clinical Features

HAIs manifest with diverse clinical syndromes, including bloodstream infections, pneumonia, urinary tract infections, surgical site infections, and device-associated infections. Clinical features are often non-specific and may overlap with community-acquired infections, but the course is frequently complicated by persistent or relapsing infection, poor response to antibiotics, and organ dysfunction. Early recognition and pathogen-specific identification are critical for effective management and infection control.

Diagnosis

Diagnosis of HAIs requires a combination of clinical assessment, microbiological cultures, molecular diagnostics, and susceptibility testing. Rapid identification of the causative organism and resistance profile is essential for targeted therapy. Advances in metagenomic sequencing and phage susceptibility assays are increasingly utilized to guide personalized bacteriophage therapy, enabling the selection of phages with lytic activity against the patient’s specific pathogen.

Treatment & Management

Conventional management of HAIs involves antimicrobial therapy, source control, and supportive care. However, MDR infections often necessitate combination regimens or salvage therapies with limited efficacy. Bacteriophage therapy introduces a novel therapeutic axis by administering phages intravenously, topically, or via inhalation, depending on infection site. Compassionate use cases and early-phase clinical trials have reported favorable outcomes in otherwise refractory infections, particularly in prosthetic joint infections, bacteremia, and respiratory tract infections. Adjunctive use with antibiotics may enhance bacterial clearance through synergistic interactions and reduction of bacterial resistance.

Recent Advances / Emerging Therapies

Recent years have witnessed significant progress in phage engineering, formulation, and regulatory frameworks. Synthetic biology enables the design of recombinant phages with expanded host range, enhanced lytic activity, and reduced immunogenicity. Phage cocktails are being developed to circumvent the narrow host specificity and prevent resistance emergence. Delivery systems such as encapsulation and hydrogels improve phage stability and bioavailability at infection sites. Ongoing clinical trials are evaluating the efficacy and safety of phage therapy for osteomyelitis, cystic fibrosis-associated lung infections, and catheter-related bloodstream infections. In vitro and animal studies support the potential for phage-antibiotic synergy, biofilm disruption, and eradication of dormant bacterial populations.

Guideline Recommendations

While regulatory approval for phage therapy remains limited, expert consensus and provisional guidelines advocate its use in select scenarios: culture-proven MDR infections unresponsive to antibiotics, compassionate use under investigational protocols, and as adjunct therapy in complex biofilm-mediated infections. The European Medicines Agency and FDA have issued pathways for compassionate use and expanded access, emphasizing individualized phage selection, quality assurance, and robust monitoring. Integration of phage therapy into antimicrobial stewardship frameworks and infection control protocols is under active development. Multidisciplinary collaboration involving infectious disease specialists, microbiologists, and regulatory authorities is essential for optimizing clinical outcomes and minimizing risks.

Conclusion

Bacteriophage-based therapeutics represent a promising adjunct or alternative to conventional antibiotics for the selective elimination of healthcare-associated pathogens, particularly in the context of multidrug resistance. Advances in phage biology, delivery systems, and regulatory frameworks have propelled this modality toward clinical translation. Continued research, well-designed clinical trials, and standardized guidelines will be critical for defining the role of bacteriophage therapy in routine clinical practice, ultimately enhancing patient outcomes and infection control in healthcare settings.